Abstract
This study has retrospectively analyzed the efficacy of single-agent prednisone, usually given after failure of other therapies, in 30 patients with myelofibrosis (MF) and severe anemia. Initial dose was 0.5–1 mg/kg daily, with tapering to the minimum effective dose in responders. Twelve patients (40%) achieved anemia response according to the revised International Working Group for Myelofibrosis Research and Treatment criteria, after a median time of 1.1 months on treatment. Median response duration was 12.3 months. Patients with constitutional symptoms or > 2% circulating blasts had a trend for a lower response rate. A platelet increase > 50 × 109/L was observed in three out of 11 patients with baseline counts < 100 × 109/L. Median survival from prednisone start was significantly longer in anemia responders (5.0 years, 95% CI = 3.5–6.5, vs 1.5 years, 95% CI = 0.2–2.8; p = 0.002). Prednisone can improve the anemia and thrombocytopenia in selected MF patients after failure to standard therapies.
Potential conflict of interest
Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal
This work was supported by the grant RD12/0036/0010 from the Instituto de Salud Carlos III, Spanish Ministry of Health.